The National Academies of Sciences, Engineering, and Medicine released a report on transforming ALS into a manageable, chronic disease within 10 years, but it falls short in accelerating treatment development. ALS is a devastating condition with no effective treatments for 99% of patients. The report focuses on improving access to care, genetic testing, and caregiver support, but lacks a comprehensive strategy for accelerating drug development. A better approach would involve targeting TDP43 malfunctions, developing precision therapies based on ALS subtypes, and investing in brain-computer interfaces for speech. Collaborations between organizations are needed to drive genuine innovations in ALS research and treatment development.
Source link
An ALS moonshot plan barely gets off the ground
